[A new therapeutic principle for migraine].
Ashina
Messoud
M
Dansk Hovedpinecenter, Neurologisk Afdeling, Glostrup Hospital, DK-2600 Glostrup. ashina@dadlnet.dk
Jensen
Rigmor Højland
RH
D001381:Azepines / Q000008:administration & dosage / Q000627:therapeutic use; D015740:Calcitonin Gene-Related Peptide / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D007093:Imidazoles / Q000008:administration & dosage / Q000627:therapeutic use; D008881:Migraine Disorders / Q000188:drug therapy*; D010879:Piperazines / Q000008:administration & dosage / Q000627:therapeutic use; D011799:Quinazolines / Q000008:administration & dosage / Q000627:therapeutic use; D017366:Serotonin Receptor Agonists / Q000008:administration & dosage / Q000627:therapeutic use; D016896:Treatment Outcome; D014230:Triazoles / Q000008:administration & dosage / Q000627:therapeutic use; D014363:Tryptamines / Q000008:administration & dosage / Q000627:therapeutic use; D014665:Vasodilator Agents / Q000008:administration & dosage / Q000627:therapeutic use*
D001381:Azepines; D007093:Imidazoles; D010879:Piperazines; D011799:Quinazolines; D017366:Serotonin Receptor Agonists; D014230:Triazoles; D014363:Tryptamines; D014665:Vasodilator Agents; C093622:rizatriptan; C525458:telcagepant; D015740:Calcitonin Gene-Related Peptide; C406305:olcegepant